188 related articles for article (PubMed ID: 15656032)
21. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
Nilsson B; Sjölund K; Kindblom LG; Meis-Kindblom JM; Bümming P; Nilsson O; Andersson J; Ahlman H
Br J Cancer; 2007 Jun; 96(11):1656-8. PubMed ID: 17533389
[TBL] [Abstract][Full Text] [Related]
22. [Gastrointestinal stromal tumors: case reports and review of the literature].
Bronzino P; Colombini M; Ferro A; Gambetta G; Gennaro M; Ivaldi L; Revetria P
G Chir; 2008; 29(1-2):33-7. PubMed ID: 18252146
[TBL] [Abstract][Full Text] [Related]
23. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
Ando Y; Tsunoda T; Beck Y; Takayama T; Tahara H
Surg Today; 2005; 35(2):157-60. PubMed ID: 15674500
[TBL] [Abstract][Full Text] [Related]
24. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
[TBL] [Abstract][Full Text] [Related]
25. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
[TBL] [Abstract][Full Text] [Related]
26. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
Neuhaus SJ; Clark MA; Hayes AJ; Thomas JM; Judson I
ANZ J Surg; 2005 Mar; 75(3):165-72. PubMed ID: 15777399
[TBL] [Abstract][Full Text] [Related]
27. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Eisenberg BL; Judson I
Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
[TBL] [Abstract][Full Text] [Related]
28. [Gastrointestinal stromal tumors (GIST)].
Reichardt P; Pink D; Mrozek A; Lindner T; Hohenberger P
Z Gastroenterol; 2004 Apr; 42(4):327-31. PubMed ID: 15095124
[TBL] [Abstract][Full Text] [Related]
29. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
30. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Láng I; Hitre E
Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
Papaetis GS; Syrigos KN
Cancer Metastasis Rev; 2010 Mar; 29(1):151-70. PubMed ID: 20112054
[TBL] [Abstract][Full Text] [Related]
32. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
33. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
34. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal stromal tumors.
von Mehren M; Watson JC
Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
[TBL] [Abstract][Full Text] [Related]
36. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
37. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
39. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
40. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Renouf DJ; Wilson L; Blanke CD
Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
